Philip Tipton, MD, Mayo Clinic, Jacksonville, FL, provides updates on anti-amyloid therapies used to treat Alzheimer’s disease (AD). Five drugs with progressions in clinical trials over the past year include aducanumab, gantenerumab, solanezumab, donanemab, and lecanemab. The latterly mentioned lecanemab has had the most promising progress and met the primary outcome of the Clarity AD trial (NCT03887455). Results from Phase III showed a significant difference in the increase of Clinical Dementia Rating Scale-Sum of Boxes (CDR-SOB) score by 0.45 points. Lecanemab is also being studied in combination with anti-tau agents for AD treatment. Donanemab is being monitored in the TRAILBLAZER-ALZ 2 (NCT04437511) & TRAILBLAZER-ALZ 3 (NCT05026866) trials, with results from Phase III of TRAILBLAZER-ALZ 2 expected this year. Unfortunately, Phase III results of gantenerumab in the SKYLINE trial (NCT05256134) did not meet its primary outcome but is undergoing reformulation to increase penetrance through the blood-brain barrier. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.